The full Johnson & Johnson (JNJ) reaction history

Every JNJ news event with the realized, point-in-time move the market made — the same measurement, headline by headline. Back to the JNJ overview →

By year and event type

JNJ reaction counts across 4 years.

Event type2026202520242023Total
Press release8215212123378
SEC filing · Form 8-K71112838
SEC filing · Form 13F-HR544114
SEC filing · Form 10-Q23319
SEC filing · Form 11-K11204
SEC filing · Form DEFA14A11204
SEC filing · Form 10-K11103
SEC filing · Form ARS11103
SEC filing · Form DEF11103
SEC filing · Form N-PX11103
SEC filing · Form SD11103
SEC filing · Form 8-A12B01102
SEC filing · Form CERT01102
SEC filing · Form S-3ASR10001
All types10417915133467

Counts from the full measured window for JNJ, not just the free rows below — every event type we have labeled, year by year.

Archive pages

Older JNJ news pages.

Page 1 is the JNJ overview; pages 2–10 carry the rest of the measured list.

The 10 most recent JNJ reactions.

DateHeadlineEventSource5-minTo close
Form N-PX JOHNSON & JOHNSON For: Jun 30SEC filing · Form N-PXSEC EDGAR+0.28%-0.39%
Quantified Named One of the Fastest-Growing AI & Data Companies on the Inc. 5000 List for the Second Consecutive YearPress releasePR Web+0.28%-0.39%
Form 13F-HR JOHNSON & JOHNSON For: Jun 30SEC filing · Form 13F-HRSEC EDGAR-0.09%+0.42%
Form 8-K JOHNSON & JOHNSON For: Aug 04SEC filing · Form 8-KSEC EDGAR-1.31%+0.20%
Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare ConferencePress releaseBusiness Wire+0.55%+0.92%
Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective SeptemberPress releaseBusiness Wire-1.31%+0.20%
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancerPress releasePR Newswire+0.15%-1.24%
Form 8-K JOHNSON & JOHNSON For: Jul 29SEC filing · Form 8-KSEC EDGAR+0.15%-1.24%
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune ResetPress releaseBusiness Wire+0.15%-1.24%
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology InnovationPress releaseBusiness Wire+0.15%-1.24%

457 more JNJ reactions are behind a free account. Create one to see all 467 measured JNJ events — the same point-in-time reactions, every headline.

See all 467 JNJ events →

No credit card · 1,000 free credits/mo